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Capillary hemangiomas are the second most common childhood tumor of the orbit and may cause
proptosis and amblyopia if untreated. Oral propranolol has recently been reported to be an effective and
safe alternative. Herein, we describe a 2-month-old boy presented with a deep capillary hemangioma of
his left eye. It continued to enlarge rapidly and magnetic resonance imaging of the orbit demonstrated
hemangioma inﬁltration over the left superonasal orbit. The patient was treated with oral propranolol
starting at 0.5 mg/kg/day with an incremental increase of 0.5 mg/kg/day every 2 days, up to a maximum
of 1.5 mg/kg/day. The patient continued 1.5 mg/kg/day of oral propranolol for 5 months as an outpatient
without any complications. The volume of the hemangioma has decreased on the following magnetic
resonance imaging and the swollen eyelid dramatically improved after treatment. Oral propranolol at
1.5 mg/kg/day may reduce the volume of deep infantile hemangioma in the proliferative stage. Relatively
long duration and slow tapering are recommended to prevent relapse.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Infantile capillary hemangiomas are the most common benign
vascular tumors of the periorbital region and demonstrate a typical
clinical course characterized by a rapid proliferative phase during
early infancy followed by gradual involution.1 Corticosteroids are
considered ﬁrst-line therapy for problematic infantile capillary
hemangiomas. A dose of 2e3 mg/kg/day of oral steroid frequently
reduce the volume of lesions in the ﬁrst 2 weeks. Rebound in the
lesion size with attempted discontinuation or inadequate reduction
in the hemangioma results in continuation of the oral steroids with
an increasing chance of adrenal suppression, Cushing syndrome,
and developmental delays.2 These complications encourage alter-
native treatments of which intralesional injection of corticosteroids
remain the most popular management for periocular hemangi-
omas.3 However, intralesional steroid injections for capillary
hemangiomas with orbital involvement have risks associated withe no conﬂicts of interest.
loplastic Surgery, Department
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e Ophthalmologic Society of Taiwretroseptal or retrobulbar injection.4 In 2008, Léauté-Labrèze et al5
described the use of oral propranolol for infantile hemangiomas.
Here, we report the efﬁcacy of oral propranolol in the treatment of
capillary hemangioma with orbital involvement in a 2-month-old
infant.2. Case report
A 2-month-old boy was referred to us for a swollen and droopy
left-sided eyelid. A mass had been present since age 10 days and
had been increasing in size with resultant occlusion of the left eye
and proptosis (Fig.1A). Given the patient’s age, ptosis of his eye, and
the rapid growth of the lesion, he was felt to be at high risk for
developing amblyopia. He was admitted on the day of consultation
to the newborn intensive care unit and underwent magnetic
resonance imaging (MRI) of the orbit, as well as electrocardiogram.
The T2-weighted MRI revealed a heterogeneous tumor mass in the
superonasal orbital region with a signal intensity higher than that
of the extraocular muscles (Fig. 2A and C). The electrocardiogram
was normal. On the 2nd day of hospitalization, oral propranolol was
started at 0.5 mg/kg/day divided over three doses. Heart rate and
blood pressure were monitored every 4 hours and compared with
age-related reference ranges. With good tolerance, the dose wasan. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Infant aged 2 months with deep hemangioma. (A) Before oral propranolol treatment. (B) One month after the start of oral propranolol. (C) Five months after the start of oral
propranololdnote symmetrical eyelid position. (D) Six months after stopping oral propranolol.
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1.5 mg/kg/day. The lesion notably improved on oral propranolol. On
the 7th day of hospitalization, the boywas discharged home and his
parents were informed of the possible adverse effects and to dis-
continue immediately if poor feeding, cool and clammy skin,
breathing difﬁculty, or lethargy occurred. Follow-up after discharge
was conducted monthly, and monitoring of heart rate and blood
pressure was performed by the pediatrician at each visit. He was
treated with propranolol at a maintenance dose of 1.5 mg/kg/day
titrated to his increasing body weight. Five months later, a follow-
up MRI showed the lesion to be reduced in size from 6.38 cm3 to
2.92 cm3 by computation of volumetric data on image workstation
(Fig. 2B and D). His eyelid position was nearly symmetric. At that
point, his propranolol was tapered by 0.5 mg/kg per month
(Table 1). The propranolol was discontinued at age 9 months.
Cycloplegic refraction showed 0.5/0.50  162 OS at that time.
There was no evidence of recurrence of the hemangioma 6 months
after discontinuing propranolol (Fig. 1). Then the capillary hem-
angiomas were supposed to be in involution stage.Fig. 2. (A) Infantile hemangioma on the superonasal side of the left orbit. Magnetic reson
transaxial T2-weighted sequence with central low signal intensity dots and tubules, represe
(B) The tumor size was markedly reduced after propranolol treatment. (C) The tumor manife
left eye globe causing downward displacement. (D) Owing to tumor shrinkage after propra3. Discussion
Depending on the depth of tumor inﬁltration, capillary hem-
angiomas are classiﬁed into superﬁcial, deep, and combined hem-
angiomas. Deep infantile hemangiomas are posterior to the orbital
septum and usually lie in the deep tissue of the lid and anterior
orbit. The clinical characteristics include ptosis, proptosis, and
displacement of the globe, which are strongly associated with oc-
clusion of the visual axis, astigmatism, and strabismus resulting in
amblyopia. A group in Texas compared growth characteristics of
superﬁcial and deep hemangiomas and noted that deep hemangi-
omas are more likely to have a longer proliferative stage,6 and
indicate an increased risk of potential complications and the need
to be treated aggressively during the early stage.
There is no standard treatment for capillary hemangiomas. In
general, intralesional steroid injections have been given for peri-
orbital lesions,3 but retroseptal or retrobulbar injections for deeper
lesions may cause retrobulbar hemorrhage, bilateral arterial
embolization,7 and central retinal artery occlusion,8 leading someance imaging of the orbit demonstrated lobulated high signal intensity tumor on the
nting high ﬂow vessels without hemorrhage, phleboliths or venous lakes; scale ¼ 1 cm.
sted intense contrast enhancement on the T1-weighted image with mass effect on the
nolol treatment, the displaced eye returned to a neutral position.
Table 1
Protocol for the administration and discontinuation of oral propranolol.
Starting oral propranolol at age 2 mo
Initial dosing 0.5 mg/kg/day in 3 divided doses  2 d
1.0 mg/kg/day in 3 divided doses  2 d
1.5 mg/kg/day in 3 divided doses  2 d (ﬁnal)
Maintenance 1.5 mg/kg/day in 3 divided doses  5 mo
Taper 1.0 mg/kg/day in 3 divided doses  4 wk
0.5 mg/kg/day in 3 divided doses  4 wk
Discontinuation at age 9 mo
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injection of corticosteroids.9
Propranolol is a nonselective b-adrenergic antagonist that has
been used for many years in neonates to treat cardiovascular dis-
orders, including certain forms of tachycardia. Due to the dramatic
results reported by Léauté-Labrèze et al,5 propranolol is currently
advocated in the treatment of infantile hemangioma and fast
becoming a ﬁrst-line treatment.10 However, there are some case
reports of discontinuing propranolol treatment because of side
effects (symptomatic hypotension, bradycardia, bronchospasm,
and hypoglycemia) and tumor lysis syndrome.11,12
Currently, a standard protocol for treatment of infantile hem-
angioma with oral propranolol has not been established. An
effective therapeutic dose of 2 mg/kg/day is usually recommended
for focal and segmental infantile hemangiomas in infants younger
than 6 months.10 Although Tan et al13 reported to use the dosage of
1.5 mg/kg/day in 13 patients could achieve good response, none of
these 13 patients had lesions in the orbit. Cornish and Reddy14
reviewed the use of propranolol in the management of periocular
capillary hemangiomas. All of 11 patients with orbital extension
were treated with oral propranolol at a dose of 2 mg/kg/day. Be-
sides, Chik et al15 revealed that hemangiomas may recur after
relatively shorter courses of treatment and after relatively more
rapid tapering of therapy. In our case, low-dose propranolol was
administered at 1.5 mg/kg/day for 5 months and tapered off slowly
over 2 months until the patient was 9 months old. Six months after
discontinuing the medication, there was involution of the heman-
gioma without relapse. Mostly, infantile hemangiomas had accel-
erated growth before the age of 8 weeks16 and cessation of growth
after the age of 9 months.6 Some reports have been advocated
that oral propranolol is continued until the proliferative phase
has ended (age 6e12 months) or until stabilization of theinvolution.10,14 Depending on the clinical response, we would
suggest keeping themaintaining dose of oral propranolol beyond at
least 6 months of age and tapering should be gradual over months.
In conclusion, deep hemangiomas of the orbit should be treated
during the early stage; a low dose (1.5 mg/kg/day) of oral pro-
pranolol can effectively reduce the size without any complications.
However, a larger multicenter randomized clinical control trial is
needed to conﬁrm the safety proﬁle and efﬁcacy of propranolol for
use in the management of periocular infantile hemangioma in
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